UNSPSC 51333410: Ziprasidone

This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6UKA5VEJ6X, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- but generally known as ziprasidone, which bears US NIH Compound Identifier 60854. European Medicines Agency schedules Ziprasidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG.

UNSPSC 51333410 Ziprasidone, a Commodity code, nominally covers the pharmaceutical antipsychotic medication ziprasidone, but the recent state and local procurement activity under this code does not reflect that scope. Instead, Seminole County, Florida solicited naloxone and drug deactivation systems—opioid-reversal medication and harm-reduction equipment unrelated to ziprasidone's therapeutic class or clinical use. The single recent opportunity shows a mismatch between the code's stated commodity and the work actually being procured under it in state and local government.

Seminole County posted IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the due date was July 26, 2023. Vendors must include shipping and delivery costs in their proposals, comply with drug-free workplace and E-Verify requirements, maintain workers' compensation and general liability insurance, and commit to a two-year initial term with an optional one-year renewal. The procurement may be FEMA-funded, introducing federal compliance obligations including the Clean Air Act and Federal Water Pollution Control Act. The narrow activity under this code and the material divergence between the code's pharmaceutical scope and the naloxone / drug deactivation systems actually being solicited suggest that this code sees little relevant state and local procurement activity; the recent opportunity appears to reflect a classification error rather than a pattern of purchases aligned with ziprasidone itself.